P, [5] [6] as seen in our patient. The aneuploidy (loss of chromosomes 6 and 22) at diagnosis, and the 15-year interval between ET and leukemia, could indicate that a favorable bone marrow environment for leukemic transformation depends more on disease biology and duration, than on specific therapy. [7] [8] The current availability of targeted therapy with imitanib mesylate allowed cytoreduction with decreased morbidity, and the reduced-intensity fludarabine-based program 3 allowed donor engraftment with curative intent in the context of chronic GvHD. 1 Imatinib has been shown to inhibit the tyrosine kinase activity of BCR/ABL, but also of an increasing number of other tyrosine kinases such as ETV6/PDGFRb, c-Kit and FIP1L1-PDGFRa.
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The ETV6 gene is located on 12p13 and expressed as a 452 amino-acid protein with two regions of homology to the ETS family of transcription factors. It may be fused to various partner genes mainly coding for tyrosine kinases or transcription factors. In rare cases, it is rearranged with the ABL1 gene, producing two types of oncogenetic proteins with increased tyrosine kinase activity in vitro. 2 The low incidence of ETV6/ABL1 gene fusion in leukemia might be attributed to the opposite orientation of both genes necessitating at least three chromosomal breaks to generate a functional fusion gene. 3, 4 The clinical and morphologic presentation of ETV6/ABL1-positive leukemias is heterogenous, but eosinophilia may be a hallmark of the disease. 5 We here describe a new case of atypical myeloproliferative disorder with a cryptic ETV6/ABL1 fusion transcript detected by broad molecular screening with a multiplex RT-PCR system (HemaVisiont) and confirmed by molecular cytogenetic investigations.
A 65-year-old woman presented in April 2000 with abdominal and thoracic pain. Her history revealed a previous radical hysterectomy for an endometrium carcinoma. No adjuvant chemo-or radiotherapy was given. Laboratory tests showed a white cell count of 22 Â 10 9 /l with myeloid precursors, but normal eosinophils, platelets 63 Â 10 9 /l and hemoglobin 111 g/l. Bone marrow examination revealed an unclassifiable chronic myeloproliferative disorder. The patient received symptomatic therapy. She was readmitted 1 year later with a pancoast tumor and inguinal lymph node enlargement. Laboratory analysis revealed a leukocytosis of 25.6 Â 10 9 /l with 2% blasts and myeloid precursors, hemoglobin 80 g/l and normal platelet count. Bone marrow aspirate and biopsy were hypercellular with abnormal megakaryocytes, an increased number of eosinophils and 10% blasts. Histology of the lymph node was consistent with myeloid sarcoma. The white cell count increased rapidly up to 114.4 Â 10 9 /L, with 17% blasts and severe thrombopenia. The patient was treated with lowdose Ara-C, achieved a partial hematological response but developed an ileus and died few days later. No autopsy was performed.
Cytogenetic analysis of bone marrow cells performed at diagnosis revealed a t(5;9)(q13;q34) as the sole chromosomal abnormality. The constitutional karyotype was normal. RT-PCR for BCR/ABL was negative. Cytogenetic follow-up on bone marrow cells 11 months later revealed the presence of three abnormal clones, all characterized by the presence of t(5;9) and add(17)(q2?1). Additional abnormalities included del(5)(q13;q34) in clone 1, an additional rearrangement involving der(9) in 9q34 in clone 2 and hyperdiploidy ( þ 8, þ 11, þ 12, þ 18 and þ 19) in clone 3 ( Figure 1 ).
At this time, broad molecular screening was performed with the HemaVisiont kit (Bio RAD, Germany) ( Figure 2 ). This qualitative multiplex RT-PCR system is designed to detect 29 fusion transcripts including more than 80 breakpoints or splice variants. The cDNA is used as a template for eight parallel nested multiplex PCR reactions. The presence of a specific product in one of the multiplex reactions determines which of the eight groups of specific nested multiplex PCR to perform next. The fusion transcript can be identified after gel electrophoresis according to the group of nested multiplex PCR it belongs to and to its size. This broad molecular screening allowed to detect a ETV6/ABL1 fusion transcript. Its presence at diagnosis was retrospectively revealed from cryopreserved material and confirmed by sequencing and metaphase FISH. Hybridization with ABL probes (LSI BCR/ABL-DS translocation probes, Abbott, Switzerland) showed that the 5 0 part of the ABL gene was retained on der(9), while the 3 0 part of the ABL gene was localized on 12p (10 metaphases analyzed, data not shown). In two metaphases, the 3 0 part of the ABL gene was observed on the short arm of a second chromosome 12, indicating that the trisomy 12 observed in the hyperdiploid clone is derived from a duplication of der(12). Hybridization with cosmid 50F4 specific for the exon2 of ETV6 gene and cosmid ABL18 representing the 3 0 coding and 3 0 flanking sequences of the ABL gene revealed a fusion signal on der(12) (eight metaphases analyzed) (Figure 1b) .
Responsiveness of the leukemic cells to Imatinib was tested retrospectively on cryopreserved bone marrow cells. Cells were cultured at a concentration of 2.7 Â 10 6 /ml in RPMI 1640 medium supplemented with 10% serum, L-glutamine, penicillin and streptomycin and 0, 1 and 5 mM Imatinib Mesylate (Novartis, Switzerland). In this test model, the number of cells from normal individuals decreases, but there is no difference between untreated or Imatinib-treated cultures. In contrast, a dose-dependent decrease in cell number is seen in Imatinib-treated cultures in CML patients sensitive to the tyrosine kinase inhibition. Our patient's cells were inhibited in a dose response manner by Imatinib over the time (Figure 3) , whereas the 1 and 5 mM curves overlap in controls.
Here, we describe a patient with an unclassifiable myeloproliferative disorder where broad molecular screening revealed a rare and cryptic ETV6/ABL1 rearrangement confirmed by sequencing and metaphase FISH analysis. Our FISH results indicate that the fusion ETV6/ABL1 detected by RT-PCR results from a translocation associated with an inversion or from an inverted insertion of at least the 3 0 part of the ABL1 gene in the ETV6 gene on the short arm of the 12 chromosome. The presence of a signal on the normal chromosome 12 confirms previous observations showing that the untranslocated ETV6 allele seems to be less frequently deleted in leukemias with ETV6/ABL1 rearrangements compared to ETV6/AML1. Interestingly, the trisomy 12 observed by conventional cytogenetics in the hyperdipoid clone results from a duplication of the der(12).
Only five of the 12 published ETV6/ABL1-positive cases showed a t(9;12) by conventional cytogenetics (for reviews, see La Starza et al 5 and Keung et al 6 ) and, in one of these cases, Figure 1 Cytogenetic results. (a) Partial G-banded karyotypes illustrating the abnormalities observed in the three clones detected 11 months after diagnosis: t(5;9)(q13;q34) and add(17)(q2?1) with del (5)(q13q34) (clone 1), der(9)t(5;9)add(9)(q34) (clone 2), or þ 12 (clone 3). (b) Hybridization with cosmids 50F4 (FITC, green) and ABL 18 (Cy3, red), showing a fusion signal on the short arm of chromosome 12.
t(9;12) was involved in a three-way rearrangement. In our case, clonal evolution of the disease is suggested at the time of disease progression by additional anomalies detected by conventional cytogenetics.
This case demonstrates the complementarity of RT-PCR, conventional cytogenetics and FISH analysis in characterization of genetic alterations in hematologic malignancies.
In mice, the ETV6/ABL1 oncogene induces two different types of fatal hematologic disorders. 7 It behaves either as a progressive myeloproliferative disease very similar to CML, or as a hematologic disorder with only slightly elevated peripheral blood leukocyte count and only minimally enlarged spleen but with a severe endotoxin-mediated small bowel disease, fatty liver and acute tubular necrosis in the kidney. This supports the assumption that the ETV6/ABL1 oncoprotein plays a key role in leukemogenesis. Review of the literature shows that the disease in human is more heterogenous. Seven of the 12 cases were classified as CML, CML in blast crisis, CML-like disease or myeloproliferative syndrome, three as AML and two as ALL. In seven patients eosinophilia was reported, but none of them had clinical signs of intestinal disease. Broad molecular screening will allow prospective clinical evaluation with specific interest on the possible hallmarks of ETV6/AML1-positive leukemias such as eosinophilia and small bowel disease.
Since the ETV6/ABL1 oncoprotein has a tyrosine kinase activity similar to BCR/ABL1, these diseases might be responsive to Imatinib. This has been done with a transient response. 4 At the time of presentation of our patient, Imatinib was not yet commercially available, but we could retrospectively perform an in vitro assay which showed the sensitivity of our patients cells to Imatinib. Therefore, Imatinib can be offered as a therapeutic option either alone, or because of the only transient response in the two reported patients in combination with chemotherapy, or in the setting of stem cell transplantation.
We conclude that broad molecular screening allowed to reveal a genetically distinct entity with poor prognosis, heterogenous morphological and clinical manifestation, but with evident option of a targeted therapy. Broad molecular screening should be an integral part of diagnostics for all types of leukemias. It may detect rare diseases, provide prognostic criteria and clarify therapeutic options early on. preparations, Anne-Claude Gaide and Marianne Wicht for the determination of the constitutional karyotype and P Marynen and A Hagemeijer-Hausmann, Leuven, for providing us with the cosmid probes. We also would like to thank Regine Landmann for carefully reading the manuscript. 1 yet, the intracellular expression of Ig, CD79a, and CD79b has been less carefully evaluated. Since different mechanistic explanations have been proposed for this phenomenon, including (i) somatic mutations of the B29 gene, 2 (ii) overexpression of a product of alternative splicing of CD79b, 3 or (iii) a defect in the transport of normally synthesized BCR components to the cell surface; 4 and surface analysis cannot discern between these possibilities, we performed a thorough analysis of surface and intracellular expression of all BCR components in B-CLL cells (Indraccolo S et al, in preparation). We found a heterogeneous pattern of expression of the BCR components in 22 B-CLL samples studied, ranging from those whose phenotype was similar to normal B cells (2/22), to others which almost lacked intracellular IgM expression (3/22). The relative majority of the B-CLL samples (17/22), however, presented with a sort of dichotomy in the surface and intracellular expression levels of the BCR molecules; intracellular staining was Table 1 Effects of CD40/IL-4 activation on BCR expression in B-CLL samples
